Dry eye disease is a condition that afflicts millions of people worldwide, causing constant discomfort and affecting their quality of life. One of the key culprits behind this condition is meibomian ...

Please provide your email address to receive an email when new articles are posted on . LipiFlow has consistently demonstrated safety and efficacy in treating meibomian gland dysfunction. The review ...

Please provide your email address to receive an email when new articles are posted on . TAMPA, Fla. — At the Telling It Like It Is meeting here, Cynthia A. Matossian, MD, FACS, discusses meibomian ...

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today ...

Meibomian gland dysfunction, an etiological factor of dry eye disease, showed promising results in response to treatment with intense pulsed light. A review published in Clinical Ophthalmology found ...

Meibomian gland dysfunction (MGD) is underdiagnosed and undertreated, with asymptomatic disease far more common than symptomatic disease. As the condition progresses, patients who were initially ...

"DelveInsight’s, “Meibomian Gland Dysfunction- Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Meibomian Gland Dysfunction pipeline landscape ...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular ...

Dry eye disease (DED) affects nearly 16 million Americans. This multifactorial condition, characterized by rapid tear evaporation or decreased tear production, can cause symptoms from eye irritation ...

SANTA ANA, Calif., July 24, 2021 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies**, today revealed new comparative ...